Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
Jaime Rubio-PerezRodriguez-Perez ArMaría Díaz-BlázquezVictor Moreno-GarcíaManuel Dómine-GómezPublished in: Journal of medical case reports (2022)
Key markers are needed to better identify patients at risk of developing severe immune-related adverse events. In addition to key markers, a higher degree of suspicion and early intervention are needed to improve outcomes in acquired hemophagocytic lymphohistiocytosis, especially with the increasingly and expanding use of immune activation.